Hello, and welcome to the Third Quarter Fiscal Year 2024 Cardinal Health Incorporated Earnings Conference Call. My name is George. I'll be your coordinator for today's event. Please note, this conference is being recorded and for the duration of the call, your lines will be in a listen-only mode. I'd like to turn the call over to your host today, Matt Sims, Vice President, Investor Relations. Please go ahead, sir.

Welcome to this morning's Cardinal Health third quarter fiscal '24 earnings conference call, and thank you for joining us. With me today are Cardinal Health's CEO, Jason Hollar; and our CFO, Aaron Alt. You can find this morning's earnings press release and investor presentation on the Investor Relations section of our website at ir.cardinalhealth.com. Since we will be making forward-looking statements today, let me remind you that the matters addressed in the statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected or implied. Please refer to our SEC filings and the forward-looking statements slide at the beginning of our presentation for a description of these risks and uncertainties. Please note that during our discussion today, the comments will be on a non-GAAP basis, unless specifically called out as GAAP. GAAP to non-GAAP reconciliations for all relevant periods can be found in the supporting schedules attached to our press release. For the Q&A portion of today's call, we kindly ask that you limit questions to one per participant, so that we can try and give everyone an opportunity. With that, I'll now turn the call over to Jason.

Good morning, everyone. A year ago at our Investor Day, I reflected upon what attracted me to Cardinal Health, our strong culture, values, and mission to be healthcare's most trusted partner; how the company was uniquely positioned with its breadth and scale to navigate the complexities of the healthcare ecosystem and serve the needs of customers, manufacturers and ultimately, patients. At the same time, I was open about some of the opportunities in front of us as an organization. Together, we laid out a clear but aggressive strategic plan, streamlined our focus, and the team got to work, all the time prioritizing our core business to emerge as a stronger, more resilient company. And we have a recent proof-point. Over the last several months, we deeply focused on preparing for a variety of alternatives regarding a particular large, low margin customer contract, which has allowed us to quickly navigate the upcoming contract change and confirm that we expect to grow our earnings in fiscal '25. By driving improvements in our core operations, investing to expand our offerings in key areas like specialty and evolving our commercial approach in ways which have resonated elsewhere in the marketplace, we demonstrated that we have made progress on positioning our business for sustained success and growth. As we look ahead, the current quarter's results reinforce our confidence. We're operating from a position of growing strength and resiliency, with industry trends that remain stable and in our favor. In Q3, we delivered broad-based growth, while executing on our four strategic priorities; building upon the growth and resiliency of pharmaceutical and specialty solutions, executing our GMPD improvement plan, accelerating growth in key areas, and maintaining a relentless focus on shareholder value creation. In our most significant business, Pharmaceutical and Specialty Solutions, we again drove solid profit growth on top of a difficult comparison to last year's strong performance. We've seen ongoing stability in pharmaceutical demand, consistent market dynamics in our generics program, and strong performance in specialty, both downstream and upstream, all of which enables us to raise our fiscal '24 profit outlook for the segment to a midpoint of 9% growth. In GMPD, we are pleased to see the strong topline and bottom line performance, with an acceleration in growth reflecting further progress against the business' turnaround plan. GMPD's quarter was overall consistent with our expectations and the team is already working hard on the continued ramp-up in Q4. Among our other operating businesses, our new reporting structure implemented at the start of Q3 is reinforcing our focus on performance and purposeful investment in growth. The strong demand we are seeing across Nuclear, at-Home Solutions, and OptiFreight, fueled by favorable industry trends, excites us about the long-term potential as these markets and businesses continue to develop. And as we've optimized the financial strength of the broader enterprise, we've seen meaningful benefits below the operating line this year. Putting it all together, we're pleased to be in a position to raise our fiscal '24 EPS outlook, provide preliminary guidance for fiscal '25 of profit growth in each of Pharma, GMPD, and Other, as well as overall EPS, and reiterate our long-term targets for our businesses and enterprise. Our strategy and long-term outlook are unaltered and our team remains focused on executing our plan as we serve our customers and continue to drive our company forward. With that, let me turn it over to Aaron to review our Q3 results, fiscal '24 guidance, and early fiscal '25 outlook in more detail.

Thank you, Jason. This morning, we are reporting our financial results on the new financial reporting segment structure we implemented at the beginning of Q3. To that end, we released an 8-K on April 23, which provided the recast historical quarterly results for fiscal year '22, fiscal year '23, and fiscal year '24 through Q2, reflective of the new segmentation for Pharmaceutical and Specialty Solutions, GMPD, and Other. As we called out at the time, the new segmentation is designed to provide greater transparency, focus, and accountability across our businesses, and we are already seeing those benefits. Overall, Q3 was a strong quarter with double-digit operating earnings growth and 20% EPS growth. We accomplished that growth, while at the same time leaning in and making significant investments of time, expense and capital against our longer-term strategic plan. With both continued confidence in our strategies and a resilient business and team, we are pleased to once again raise our EPS guidance for fiscal year '24, more on that shortly. As seen on Slide 4, total company revenue increased 9% to $55 billion, reflecting revenue growth in the Pharmaceutical and Specialty Solutions segment, the GMPD segment, and in all of the businesses making up Other. We were particularly pleased to see the second consecutive quarter of revenue growth in GMPD at 4%. We are also pleased that gross margin increased 9% to $1.9 billion. While consolidated SG&A also increased just under 9% to $1.3 billion in the quarter, the increased amount reflects technology and other purposeful investments against the future of the business and higher costs to support sales growth. With strong broad-based profit growth, we delivered operating earnings of $666 million, 10% higher than last year. Moving below the line, interest and other was generally consistent with the prior year at $26 million, and our third quarter effective tax rate of 20.4% was better than we expected due to positive discrete items. As a result of our prior share repurchases, Q3 average diluted shares outstanding were 245 million, 5% lower than a year ago. As I mentioned earlier, the net result for Q3 was EPS of $2.08, reflecting growth of 20%. Now turning to the segments, beginning with Pharmaceutical and Specialty Solutions on Slide 5. Third quarter revenue increased 9% to $50.7 billion, driven by brand and specialty pharmaceutical sales growth. We continued to see strong pharmaceutical demand across product categories, brand, specialty, consumer health and generics, and from our largest customers. While we again saw robust demand for GLP-1 medications, recall that we had guided that the revenue growth rate would moderate this quarter, as it did, given the acceleration that we started to realize last year during Q3. Excluding GLP-1 sales, the segment's Q3 revenue growth would be 7%. As we previously noted, these sales did not meaningfully contribute to the bottom line. Segment profit increased 4% to $580 million in the third quarter, driven by positive generics program performance. Our generics program continued to see both volume growth and consistent market dynamics. Within our brand and specialty products, demand for COVID-19 vaccines in the quarter was, consistent with our expectations, not a meaningful contributor. As anticipated and guided, lower branded inflation than last year's relative high point was a year-over-year drag on profit growth. So, overall, we were pleased to deliver 4% segment profit growth in Pharmaceutical and Specialty Solutions, solid growth on top of an exceptionally strong quarter a year ago, which grew 23%. Turning to the GMPD segment on Slide 6. Revenue grew for the second quarter in a row by 4% in Q3 to $3.1 billion. This increase was driven by volume growth from existing customers. The GMPD segment delivered segment profit of $20 million, a $66 million year-over-year increase, driven by an improvement in net inflationary impacts, including our mitigation initiatives. GMPD continued its strong turnaround trajectory, achieving its highest level of quarterly profitability in the last two and a half years. We continue to be encouraged by the underlying improvements in the business, driven by the team's efforts against the GMPD Improvement Plan. As a reminder, the components of the former Medical Improvement Plan are now split between GMPD and Other, and the plan continues to be on track. The team achieved notable progress on inflation mitigation in the quarter, and we again saw a year-over-year improvement and growth in Cardinal Health brand volumes, providing continued fuel for the business' ongoing turnaround. Finishing with the businesses that aggregate into Other, as seen on Slide 7. Third quarter revenue increased 14% to $1.2 billion due to growth across all three businesses, at-Home Solutions, Nuclear and Precision Health Solutions, and OptiFreight Logistics. Collectively, the businesses grew segment profit in the quarter by 5%, with OptiFreight Logistics showing particular strength as we worked during the quarter to create the foundations for future profit growth in all of the businesses. Now turning to the balance sheet. We ended the quarter with a strong cash position with $3.7 billion of cash and equivalents on the balance sheet. Year-to-date, we've generated $2.1 billion of adjusted free cash flow and have continued to deploy capital according to our disciplined capital allocation framework, including investing approximately $320 million in CapEx back into the business to drive organic growth and funding the $1.2 billion acquisition of Specialty Networks. Over the past several years, we've made tremendous progress with our balance sheet. At the end of the quarter, we received a further update to our ratings outlook with Moody's moving our outlook to positive. We issued $1.15 billion in new notes during the quarter to refinance our upcoming June and November debt maturities. We plan to hold the cash proceeds and time deposits until the calendar year 2024 maturities come due. I'll note, due to the nature of these contracts, only about half of the total cash received is reflected in our Q3 ending cash balance. The remaining $550 million is recorded in prepaid expenses and other on the balance sheet. We have returned over $1 billion total to shareholders year-to-date, which includes approximately $375 million of quarterly dividend payments and $750 million in share repurchases, which is in excess of our committed baseline repurchase of $500 million. Now for our updated fiscal '24 guidance on Slide 9, beginning with the enterprise. We are raising and narrowing our fiscal year '24 non-GAAP EPS guidance. Our new range of $7.30 to $7.40 reflects a midpoint, which is 27% above our fiscal '23 EPS results. We started the year working to deliver our guidance of 14% EPS growth at the midpoint. What a year it has been so far. Before we turn to the segments, a few comments on our enterprise assumptions. With the year-to-date results, we are improving our fiscal '24 effective tax rate guidance to an updated range of 22% to 23%. And we are reiterating our fiscal '24 expectations for adjusted free cash flow of approximately $2.5 billion, for CapEx of around $500 million, for diluted shares of approximately 247 million, and for share repurchases of $750 million which, consistent with our framework, does not assume further repurchase activity this year. Now turning to the fiscal '24 outlook for our new segment reporting structure, as seen on Slide 10. With another solid quarter from Pharmaceutical and Specialty Solutions, we are raising and narrowing our segment profit guidance for the full year to 8.5% to 9.5% growth, which at the midpoint implies continued mid-single digit profit growth in the fourth quarter. We are reiterating our guide for GMPD segment profit of approximately $65 million for fiscal year '24. We continue to expect to address the impact of inflation as we exit fiscal '24, along with continued Cardinal Health brand volume growth and benefits from our continued cost savings initiatives. Additionally, we anticipate a positive impact from seasonality in Q4 compared to Q3. We are also reiterating our segment profit guide for the Other businesses, 6% to 8% segment profit growth for the full year, given that we expect a strong Q4 for those businesses. On the topline, we now expect Other full year revenue growth of approximately 12%. So, as I highlighted earlier, we are raising our guidance for fiscal year '24 to $7.30 to $7.40. Finally, let me conclude my remarks by providing a guidance preview for fiscal year '25. We will provide formal fiscal year '25 guidance during our Q4 and full year earnings call in August. However, with the benefits of our raised fiscal year '24 expectations and the action plans already underway in response to recent market changes, here is our preliminary perspective. For our largest business, Pharmaceutical and Specialty Solutions, while revenue will reset in the year as we offset a recent customer non-renewal, we notably expect to deliver at least 1% segment profit growth in fiscal year '25 before returning to more normalized growth in fiscal year '26. Looking forward, our commercial and operational teams have been busy, and our value proposition is resonating in the marketplace. Over the past several months, we have had some attractive wins with new customers and some existing customers are expanding their own footprints with us. Some of these are already under contract and ordering and others are scheduled for implementation in the second half of next fiscal year. So, over the course of the upcoming year, we expect new volume coming our way at sustainable margins. We completed the Specialty Networks acquisition quickly, which will be additive to our efforts in fiscal year '25. Separately, we have turned a further eye to optimizing our cost structure across our corporate functional footprint and across the Pharmaceutical and Specialty Solutions portfolio. Regarding environmental factors, we are expecting brand inflation to be roughly equivalent to fiscal '24 levels, while we remain watchful relative to the contribution of COVID-19 vaccines. For the GMPD segment, we expect continued growth in fiscal year '25 on our path to approximately $300 million in segment profit by fiscal year '26, driven by the annualization of inflation mitigation, progress with Cardinal Health brand growth, and continued simplification and cost optimization. We expect approximately $175 million in GMPD segment profit in fiscal year '25. And for the businesses included in Other, we expect the strong demand we've seen across these businesses to continue. With positive industry trends and the strength of our competitive positioning, we expect collective segment profit growth in fiscal year '25 at the top end of our long-term target approximately 10%. During fiscal '25, we will be investing across all of our businesses, with key examples being new facilities like our Consumer Health Logistics Center, at-Home Solutions facilities in Texas and South Carolina, and further geographic reach of our Nuclear and Precision Health Solutions' PET network. We will also continue our build-out of Navista and investments in GMPD supply chain resiliency. Now a few call-outs below the line and with the balance sheet. We anticipate a significant step-up in interest and other next year, primarily due to much lower average cash balances due to cash already deployed for Specialty Networks and due to the one-time unwinding of negative net working capital from the large contract non-renewal. We also expect lower short-term investment rates on cash and higher interest rates on debt resulting from the refinancing of our calendar 2024 maturities, leading to an interest and other range of $160 million to $190 million in fiscal year '25. We expect our fiscal year '25 effective tax rate to be in the range of 23% to 24%, slightly higher year-over-year due to discrete favorability seen this year. Partially offsetting these impacts, we would expect a lower share count between 244 million and 245 million due to the $500 million of baseline share repurchases we've previously outlined. Finally, while we continue to expect to generate adjusted free cash flow of approximately $2 billion on average from fiscal 2024 to 2026, we think it is important to call out that fiscal 2025 will be lower than that average, primarily due to the large contract unwind, as well as quarter end day of week timing. These dynamics will significantly influence our cash flow in Q1 of next year. However, our strong investment grade balance sheet positions us well to manage through these fluctuations. With respect to the long term, it is full speed ahead. We are reiterating our fiscal year '24 through '26 targets for the enterprise and segments and expect to deliver at least $7.50 of non-GAAP EPS in fiscal year '25, which reflects at least 30% total EPS growth on a two year basis. With that, I will turn it back over to Jason.

Thanks, Aaron. Now for some additional perspective on our businesses, beginning with Pharmaceutical and Specialty Solutions, where our focus remains executing in the core to build upon our strong foundation. We're continuing to invest in our core business to drive operational efficiency and provide improved customer focus capabilities. At the same time, we have been evolving our commercial engagement strategies to get closer to the customer, better understand their complex needs, and provide proactive solutions. As an example, we've highlighted our first to market clinically integrated supply chain, the Cardinal Health InteLogix Platform, which deploys AI and machine learning through the Palantir Foundry platform to analyze real-time clinical and purchasing data to help providers reduce costs, optimize drug inventories, and streamline medication supply. We've also developed the Cardinal Health Atrix Elements offering, which is a suite of hospital reimbursement services that help improve hospitals' workflows and efficiencies. We've driven tremendous progress in our services for health systems, leading to the successful onboarding of a new key customer and additional new health system business coming in fiscal '25. We recently broke ground on our new 350,000 square Consumer Health Logistics Center in Central Ohio that we see as a differentiator in the marketplace. Over the past several years, we've experienced growing demand for over the counter consumer health products, which are an important part of our offering for retail pharmacy customers, particularly among our valued retail independent community pharmacies. With innovative technology and automation solutions powering the new facility, which will serve as a centralized replenishment center, we anticipate improved inventory efficiency across our network and providing unparalleled supply chain responsiveness for our customers. We see the rapid development of advanced automation technologies as an ongoing opportunity for our business. During the quarter, we deployed new sortation systems in a number of our distribution centers with a continual focus on employee safety, customer service, and operational efficiency. Turning to specialty, where we have and will continue to invest to accelerate our growth. As Aaron noted, our integration of Specialty Networks is underway and the reaction from the providers we serve and the energy from our new teammates has been extremely encouraging. Specialty Networks' mission as part of Cardinal Health remains creating clinical and economic value for independent physicians by lowering costs, operating more efficiently, and helping them deliver best-in-class care to their patients. We see greater opportunities together with the business' multi-specialty platform, proprietary technology, and deep clinical expertise being a natural extension of Cardinal Health's suite of solutions for specialty practices across the country. Specialty Networks expands our offerings with physicians in the areas of urology, GI, and rheumatology, while providing a proven platform in PPS analytics that we'll further invest into in fiscal '25 and look to extend to other therapeutic areas such as oncology. The platform's insight generation capabilities for clinicians are robust, which accelerates our upstream data and research opportunities with biopharma manufacturers. We see these and other capabilities as supporting our ongoing build-out of Navista, our clinician-designed oncology practice alliance, offering advanced services and technology. Navista's mission is to unlock the power of community oncologists to secure their independence and revolutionize patient centered cancer care. This build-out continues to progress according to plan as we actively pilot next-generation technologies and capabilities with select oncology practices. Upstream with manufacturers, we saw a strong performance from our biopharma solutions business during the quarter. With scaled assets, differentiated solutions, and a tenured team of experts, our leading specialty 3PL has supported 23 launches year-to-date through March with more anticipated in the coming quarters. Our 3PL and regulatory consulting capabilities helped pioneer the commercialization of the first CAR T-cell and gene therapies years ago, and we continue to bring innovative services to the market. Opening in May, our Advanced Therapy Innovation Center that features a deep frozen storage suite will support the complex storage requirements of cell and gene therapies. And we've seen our Advanced Therapy Solutions and Nuclear, Precision Health Solutions businesses successfully collaborating in support of cell and gene manufacturers. Turning to the GMPD business, where we're executing our GMPD Improvement Plan. We continued to drive momentum across the business in Q3 with strong sequential segment profit growth and significant improvement versus prior year. During the quarter, we offset approximately 90% of the gross inflation impact on our business, through the execution of our mitigation initiatives, commercial contracting efforts, and the continued realization of reduced costs for international freight, we're on track with our target to address these impacts by the time we exit fiscal '24. We are pleased to achieve 4% topline growth in the quarter, reflecting the improving health of our business. We saw growth across Cardinal Health brand and core distribution and in our domestic and international businesses. Specifically, our 5 point plan to grow Cardinal Health brand volumes continues to show positive trends across the key leading indicators. Our customer loyalty index score for U.S. distribution has increased by 14 points in the past two years and is up over 20 points from its pandemic low a few years ago. We successfully retained key distribution customers and the team is gearing up for some new customer implementations in the months ahead. Our product back orders remain near multi-year lows and we've continued to develop and commercialize new products, such as our Kendall pediatric sleeve to prevent deep vein thrombosis risk in young patients. We've noted our investments in the resiliency of our supply chain to better service our customers. In Q3, our efforts were recognized as the first distributor to achieve the highest rating by Healthcare Industry Resilience Collaborative's resiliency badge program, a key industry benchmark of our progress. Finally, we are executing our simplification initiatives across our business with a continued focus on optimizing our cost structure and global manufacturing and supply chain. In Nuclear and Precision Health Solutions, we're realizing continued double-digit growth in Theranostics, driven by the successful launch execution of new and advanced Theranostics in oncology. For example, we have realized meaningful growth in fiscal '24 from the adoption and growing demand of prostate cancer radio diagnostics, which are an important tool for healthcare providers to assess and properly treat the disease. We see a large, growing, and diversified pipeline, positioning our business to deliver value long into the future. The pipeline consists of more than 60 opportunities across oncology, cardiology, and neurology that are either contracted, in negotiations, or being actively explored with pharmaceutical companies. As an example, in oncology, we look forward to expanding our support level of novel prostate radioligand therapies in fiscal '25. As we look into the future, when you consider the strength of the Theranostics pipeline, only a handful of successful products are needed to deliver the strong growth outlined in our long-term targets. Our at-Home Solutions plays an instrumental role in providing patients and caregivers the critical products and services they need for care in the home. We continue to see strong demand for home healthcare and over the past decade, we've grown from servicing about 1 million customers annually to around 5 million today. Our business is positioned to accelerate in the coming years as we invest to expand the capacity of our network, the breadth of our offering, and deploy new automation technology. We're excited that our new distribution center being built in South Carolina, featuring the fastest order fulfillment system per square foot in the market, is scheduled to open by early next fiscal year. In OptiFreight Logistics, we continue to hear from our customers the value of our TotalVue Insights technology platform is providing as they seek to control their shipping spend and drive performance. Our technology provides action driving analytics and benchmarks with shipping status and delay visibility. We continue to invest in new technology driven solutions, and true to our commitment to innovation, we collaborate side-by-side with customers. For example, this quarter, we successfully co-developed and introduced a tailored pharmacy shipping solution with a strategic customer across multiple facilities. Across our businesses, opportunities are everywhere we look. We've affirmed our long-term targets for the enterprise and segments, which reflects Cardinal Health's ability to achieve sustained growth and deliver attractive returns for shareholders through an ongoing focus on value creation. We continue to prioritize the prudent management of our balance sheet and responsible capital allocation. We remain well-positioned with the financial flexibility to continue investing in our business and returning capital to shareholders. As part of our simplification journey, we are taking proactive actions to optimize our future cost structure and enhance our ability to grow well into the future. During the quarter, we took substantial steps to reduce our corporate real estate footprint and reorganized certain teams for greater efficiency and effectiveness. Our business review committee continues to make progress on our ongoing review of the GMPD business. We have no further updates to share today, but plan to keep you apprised of our progress. Driving the improvement plan remains our near-term priority and the team is making excellent progress. To close, we've had a strong first three quarters of the year and are focused on sprinting through the tape. Plans are in place to deliver growth in fiscal '25 and beyond, and we're eager to continue delivering for our many stakeholders. None of this would be possible without our highly engaged and talented team, who continues to lean in, drive our company forward, and fulfill our critical role as healthcare's most trusted partner. With that, we will take your questions.

Thank you very much, sir. Our first question today is coming from Lisa Gill coming from JP Morgan. Please go ahead.

Good morning, and thanks for taking my question. Jason, I just really want to dig into the 2025 guidance that you've given, especially when we think about RX and specialty business. We clearly know that revenue will be down because of the change RX, because of the Optum RX contract, but...

Very sorry about that, gentlemen. Her line appears just to have dropped. So if she could just maybe dial back in, I will put her back in the queue. But now, we will move to Michael Cherny. Please go ahead.

Good morning, and hopefully, my line won't drop. I probably had a similar question on Lisa, so hopefully you can address this directly. Relative to the '25 segment EBIT, as you think about the moving pieces here, maybe a two-part question. First, is there any way you can give us an underlying growth rate beyond the loss of Optum? And then second, as you think about the at least 1% segment performance, can you give us just a further breakdown on how much of that is volume growth versus mix versus new customers? Any more color you can provide on that as we think about the jumping off point and then how that factors into '26 would be great. Thanks so much.

Good morning. This is Aaron. Thank you for your question. I’d like to provide some additional context. The PS&S team has solid plans for 2025 as they continue to build on a strong fiscal 2024. Our long-term guidance for PS&S has been a profit growth of 4% to 6%. In comparison, we are now expecting at least 1% profit growth in that segment. The difference should be viewed as the net impact of profit relative to the Optum business. If we take the midpoint of our long-term guidance, which is 5%, each percentage point corresponds to approximately $20 million. By applying this to the at least 1% growth we have projected, that translates to about an $80 million net impact that we are navigating. Regarding revenue, fiscal 2023 accounted for about 16% of our overall revenue. Fiscal 2024, which is still ongoing, is projected to yield between $35 billion and $40 billion in revenue. However, it’s important to note that the portfolio continues to grow at around 10%. On the cash flow front, I hope you noted my comments about maintaining an average of $2 billion in adjusted cash flow annually during the 2024 to 2026 timeframe. While we anticipate lower cash flow in 2025 due to factors like the negative working capital from a non-renewed contract and a days of week impact, we find this manageable. I trust you will recognize the growth strategy we have for PS&S and the plans we have in place. Jason, do you have anything to add?

I'll elaborate on the factors influencing our outlook for 2025. As Aaron mentioned, the net change is approximately $80 million when considering various reference points. This suggests that the impact from Optum is likely higher, but this is somewhat offset by several positive developments we've identified. One of these is the progress we've made with other customers, indicating that our value proposition is resonating well, leading to favorable win rates in different sectors. This will help us partially mitigate the expected impact, contributing to that net $80 million figure, along with the addition of Specialty Networks. Overall, we anticipate strong growth in the specialty area, enhanced by the acquisition of Specialty Networks that closed last month, which will provide a year-over-year benefit over the next three quarters as it factors into our fourth quarter and continues to grow. Additionally, we see potential for further cost reductions by streamlining and simplifying our processes. We are optimistic about these offsets, which brings us to the net increase of about 4 percentage points that we are currently highlighting.

Next question, please.

Good morning, everyone. Jason, I have a question about the competitive landscape in the specialty sector. The industry has remained relatively stable without significant contract changes for some time, although we've seen two recently. Given the current makeup of assets in the pharmaceutical sector, are you noticing an increased demand for integrated services where clients are looking for core pharmaceutical distribution combined with other specialty areas, particularly in oncology? How do you manage the variety of solutions you provide as competition changes?

Thank you for the question, George. When I consider the competitive environment, I believe it remains quite rational overall. Although there have been a few contracts changing hands, most contracts remain stable at renewal. This stability doesn't alter our fundamental role in safely and efficiently delivering products for our customers. Your question about potential evolution in our services is important. We are continually expanding our full suite of services to meet the evolving needs of our customers. They are always seeking ways for us to add value, which varies from customer to customer. Our goal is to enhance our capabilities on both ends of the supply chain so we can serve as a comprehensive supplier and partner, supporting their business growth.

George, I would add one further thought, which is, as you see from examples like our acquisition of Specialty Networks, of course, we continue to work to get closer to the ultimate practitioner, so that we are prepared to offer the incremental services that the industry is demanding.

Thank you. We'll now move to Lisa Gill of JP Morgan. Please go ahead again.

Good morning, and thank you, and hopefully, this time it will work. So my question was actually asked, but I wanted to just really dig in just a little bit deeper. As I think about the cadence for 2025, I know you're not giving specific guidance, but maybe even first half, second half, as we think about some of the comments you made, for example, simplifying costs, right, that'll...

Okay. I apologize for the interruption. It seems we're experiencing some technical difficulties as her line has disconnected.

I believe we can grasp the intent behind her comments regarding the differences between the first half and the second half of the year. It's important to discuss the factors influencing our results and their timing. The customer migration is likely to create a significant drop at the end of the fiscal year, specifically from June 30 to July 1, which marks the start of the new fiscal year. We expect to see a notable decline in volume during the first quarter. Meanwhile, some of the new business we've secured is gradually integrating, with most of it projected to have an impact in the second half of fiscal 2025. Therefore, the timing of these factors will lean more towards the latter half of the year. Particularly for the networks I mentioned, this will provide a beneficial tailwind for us. It's factored into our fourth-quarter guidance, but we anticipate seeing improvements year-over-year for three quarters due to this new business and the expected overall growth in utilization next year. Our cost management strategies will vary; some actions have been in the works for a while and will be implemented by year-end. Others will require additional time to adjust operations to the lower volume. This customer, while large and expanding, had many unique and customized processes with a somewhat unpredictable demand profile. We will be able to run more efficiently as the volume decreases, though it won't happen instantly. It will take time for each site to adapt to the new products while also optimizing existing ones. We anticipate some mitigation of these factors right at the start of the fiscal year, with improvements developing throughout the year.

Thanks.

Good morning, and thanks for taking the questions. We've heard anecdotally that generic prices are a little bit firmer this time versus maybe last year. Can you talk a little bit about buy side and sell side pricing here of generics and maybe how gross profit dollars in that part of the business in generics are trending versus...

So, thanks for the question. What we would tell you is, as we continue to be in an environment of consistent market dynamics, where we see stability on the buy and the sell within our generic business. As we've talked about in the past, the stability that comes with that is when we see a rising tide of volume and a strong prescription demand environment, which we have, we continue to see strength in the generics portfolio, and that's where we are. We are aware that others have made comments somewhat variant from that over time, but we see consistent market dynamics and view that stability as a strength of our portfolio.

Thanks. I'll try to ask quickly before it gets dropped. Can you help us bridge on the medical side sort of the inputs to get to your fiscal '25 operating income from sort of where we are today? What are the most important factors that will get us from sort of where we are with the run rate through fiscal 3Q of '24 to the expected numbers in fiscal '25? And then just a quick follow-up. Does the loss of Optum and your partner in Red Oak also lost a large payer contract. Has that affected Red Oak in any way, shape, or form or your purchasing power or your economics there? I'm just wondering how to think about that, because it's two sizable chunks of business, but I just don't know how to think about the impact on Red Oak. Thank you.

I’ll begin by discussing the med cadence and then hand it over to Jason for more details about Red Oak. In terms of the GMPD business, we are progressing according to the plan we've been discussing for several quarters. For fiscal year '23, we reported a negative $165 million, but for fiscal '24, we currently anticipate a positive $65 million, representing a $230 million turnaround. This brings us halfway to our fiscal '26 goal of $300 million. For fiscal '25, we expect to see approximately $175 million, which is essentially a midpoint between the two figures. The key to reaching these targets lies in our continued effort to mitigate inflation, which we've discussed extensively. We finished Q3 with about 90% success in inflation mitigation and expect full mitigation by the end of the fiscal year. As we enter next year, we will be comparing to a lower percentage execution, which will provide a favorable impact, particularly in the first half and throughout the year. Additionally, it’s crucial that we maintain healthy revenue growth, especially with the Cardinal Health brand as it represents a more profitable segment of our business. In Q1, we noted a positive trend in revenue for that division, with 2% growth in Q2 and 4% growth in Q4. We are observing progress that supports our confidence in achieving both the $65 million target this year and the $175 million target next year. Lastly, our team will continue their work on simplification and cost reduction, as it has been a complex business, and they have done well in identifying cost-saving opportunities. This effort will carry on into next year as well. Jason, would you like to add anything regarding Red Oak?

Nothing to add on that component. As it relates to Red Oak, we feel very good about the scale and competitiveness of that joint venture we have with CVS. The combined volume that we both bring is sufficient to have significant scale in the space. The percentage of volume that was related to the lost customer is quite small relative to the total that we have that remains. So we feel good about continuing to provide value for our partners, our customers, and driving supply as much as possible.

Next question, please.

Thank you. A couple of modest items relative to Pharma that I wanted to tick through. One is, in discussing the headwind, penciling out to $80 million, you used the comment so far once or twice. Is that so far reflecting that there may be more mitigation or that this is influx? That would be one. Number two, is there a contemplation of any incentive comp reduction in '25 that would then reset in '26 in that mitigation? And the last one is, Specialty Networks, it sounds like you're expecting a benefit at the op profit line. I believe the comment when you closed it was it would be accretive 12 months following close. Any commentary on contribution there would be helpful as well. Thank you.

We experienced a shift in growth a couple of quarters ago, evident in our overall revenue increase, which is partly attributed to the growth of the Cardinal Health brand. For instance, this quarter, our revenue growth of 4% was reflected in both national and Cardinal Health brands, indicating a stabilization in distribution. We have secured new business that enables us to grow at or slightly above market levels, and we anticipate this growth will continue. As Aaron pointed out, the primary factor contributing to profit performance from 2024 to 2025 is the annualization of inflationary pressures, which accounts for the projected $100 million to $110 million year-over-year profit improvement. Additionally, Cardinal Health brand volume growth, cost reductions, and other initiatives will play a role, although they are not the main drivers. Looking ahead to 2026, the main contributors to growth will be Cardinal Health brand volume and further cost reductions as we work to streamline our operations. While we won’t disclose the specific elements, these are the primary drivers of growth moving into 2026.

Next question, please.

Hey, guys. Most of my questions have been asked, but I was hoping to just get an update on Navista and any metrics you're able to share on the market adoption you're seeing there, number of providers aligned to it, etc. And I know one of the key strategic objectives of the Specialty Networks acquisition was to kind of integrate some of their technology, notably PSS Analytics into Navista and other specialty assets. I'm also curious if you can provide an update on how quickly you can integrate that technology and Murphy, you've already kind of started on that path. Thank you.

Thank you for the question, Daniel. Regarding Navista, we are making solid progress on the plans we announced approximately a year ago. To summarize our advancements, I would highlight a few key areas. Firstly, we have successfully assembled an excellent team, blending internal and external talent. We’ve drawn from individuals with industry experience who understand the landscape, while also incorporating our own experts from different therapeutic areas, creating a well-rounded group. This new team has swiftly defined what we present to our customers and prospects, actively listening to their needs to operate their practices more efficiently and effectively. This engagement led us to identify the tools and capabilities we are developing within Navista. We are not just creating in isolation; instead, we are tailoring our offerings based on the specific demands of our customers, especially independent community oncologists, to enhance their operational efficiency and patient care. This is an ongoing process that builds our capabilities incrementally as we work with both existing and potential customers to integrate them into our network and determine what services they will use. Regarding the Specialty Networks, we now have a technological and capability foundation to complement our previous offerings. Navista has always aimed to incorporate the best elements from the industry. While our existing tools are valuable, we are also leveraging third-party partners to fulfill our customers' and providers' needs, ensuring we prioritize their requirements as we shape our services. We recognize the relevance of Specialty Networks and their PPS Analytics platform, but we will not prioritize that element until we understand our customers' needs better and decide which features to integrate. Decisions concerning Specialty Networks are still in progress. However, I can say that from day one, the expertise and insights of their team have greatly benefited our Navista team. As I mentioned during the announcement of the Specialty Networks acquisition, while the assets and business are impressive, the most crucial aspect for us is their leadership and the skills they bring, which have proven to be as valuable as we anticipated. We are currently seeing this dynamic in action as we collaborate not only within Navista but also across the broader business to enhance our capabilities in all therapeutic areas.

Thank you very much, gentlemen. Ladies and gentlemen, that will conclude today's question-and-answer session. I turn the call back over to Mr. Jason Hollar for any additional or closing remarks. Thank you.

Yeah. Thank you. Just to close, appreciate everyone spending some time with us this morning. We hope the overall message that you took away from the call today is that we have a strong and resilient business and a very clear plan for us for '25 and '26, and we're excited about the opportunities and ensuring that our customers and their patients continue to get fantastic service. So thanks again for joining us today and have a great day.

Thank you very much. Ladies and gentlemen, that concludes today's presentation. Thank you for your attendance. You may disconnect. Have a good day and goodbye.